Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial
D Angus, C Herd, C Stone, J Stout, M Wieler, R Reilmann, CW Ritchie, ER Dorsey, K Helles, E Kayson, D Oakes, HD Rosas, C Vaughan, PK Panegyres, D Ames, A Goh, P Agarwal, A Churchyard, M Murathodizic, P Chua Show all
The Lancet Neurology | ELSEVIER SCIENCE INC | Published : 2015
BACKGROUND: PBT2 is a metal protein-attenuating compound that might reduce metal-induced aggregation of mutant huntingtin and has prolonged survival in a mouse model of Huntington's disease. We aimed to assess the safety, tolerability, and efficacy of PBT2 in patients with Huntington's disease. METHODS: In this 26-week, randomised, double-blind, placebo-controlled trial, adults (≥25 years old) with early-stage to mid-stage Huntington's disease were randomly assigned (1:1:1) by a centralised interactive response system to once daily PBT2 250 mg, PBT2 100 mg, or placebo. Randomisation was stratified by site with a block size of three. Participants, carers, the steering committee, site investig..View full abstract
Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES
Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Prana Biotechnology Limited.